Europe
The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.
AstraZeneca and Merck are closing out 2019 on a high note with another approval for its PARP inhibitor Lynparza.
With the holidays, it’s not surprising that it was a quiet week for clinical trial news. Nonetheless, some companies did have clinical trial stories to report. Here’s a look.
CELLINK’s production is completed in-house without middlemen – this unique advantage enables a workflow with high quality assurance and short lead times.
Sphingotec reports study data demonstrating that its proprietary renal function biomarker penKid(R) (Proenkephalin) predicts acute kidney injury (AKI), multi-organ failure and mortality in sepsis patients presenting to the emergency department (ED).
Dutch life sciences investor Aglaia Oncology Funds, officially launches its ‘Life Sciences Impact Suite’, a groundbreaking tool enabling measurement and reporting of the social impact realized by investments, alongside financial performance.
Zelluna Immunotherapy announces the appointment of Namir Hassan as chief executive officer.
A comprehensive map of genes necessary for cancer survival is one step closer, following the validation of the two largest CRISPR-Cas9 genetic screens in 725 cancer models, across 25 different cancer types.
CEVEC’s CAP®Go technology enables CellGenix to offer rh TGF-ß1 in preclinical and now also in GMP-grade quality, allowing a seamless transition from preclinical to clinical development and commercial manufacturing of cell therapy products
The Sartorius AI Lab (SAIL) conducts research in the use of artificial intelligence in Sartorius platform solutions for the biopharmaceutical industry
PRESS RELEASES